真实世界鹿瓜多肽注射液治疗骨折的中医证候与节气分析

目的：通过对使用鹿瓜多肽注射液的骨折患者进行相关信息分析,了解该患者中医临床特征。方法：该研究以2003-2014年全国26家三甲医院信息系统（Hospital Information System,HIS）中使用鹿瓜多肽注射液治疗骨折的住院患者为研究对象,分析其一般信息、中医证候和发病节气。结果：45-64岁患者最多,占39.84%,其中18-44岁男性患者使用较多,占43.38%;45-64岁女性患者较多,占44.33%。入院与出院患者主证均为气滞血瘀证,分别占总人数的60.53%、53.08%;立夏和雨水两个节气入院患者最多,分别占总人数的5.26%、5.24%。结论：使用鹿瓜多肽注射液治疗骨折患者以中老年人居多,患者病证以气滞血瘀证居多,立夏、雨水入院患者居多。为临床骨折治疗时应中医辨证论治,顺应疾病本身特点及节气变化,辨证用药的特点提供理论基础。     

Increased oxidative protection by high active vitamin E content and partial radiation crosslinking of UHMWPE

Vitamin E stabilization successfully improved long‐term oxidation resistance of wear‐resistant ultra‐high‐molecular‐weight polyethylene (UHMWPE) used for joint implants. Stabilization can be achieved by blending an antioxidant into the UHMWPE resin powder before consolidation and irradiation. Balancing the wear resistance and vitamin E content in the blend is the current challenge with this approach, because vitamin E hinders crosslinking of UHMWPE during irradiation, which decreases wear resistance. The vitamin E concentration in the blend is generally limited to less than 0.3 wt%. Wear‐ and oxidation‐resistant UHMWPE has been obtained previously by consolidating blends of pre‐irradiated UHMWPE powders (XPE) into an unmodified polyethylene matrix (PE), where the improvement in wear rate depended on the radiation dose and fraction of XPE. We hypothesized that increasing the vitamin E content in the unirradiated matrix would not compromise wear and would further improve the oxidative stability of XPE/PE blends. Pin‐on‐disk wear testing showed that the XPE/PE blends containing 0.1–1.0 wt% vitamin E in the matrix had comparable wear rates. We used an aggressive accelerated aging test in the presence of the pro‐oxidant squalene and oxidation induction time (OIT) test and found that higher amounts of vitamin E resulted in stronger oxidation resistance for XPE/PE blends. The mechanical strength and toughness of the blends were not affected by changing the vitamin E content in the matrix. Stabilizing UHMWPE with higher vitamin E content may extend the service life of UHMWPE implants. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1860–1867, 2018.

     

Can tranexamic acid conserve blood and save operative time in spinal surgeries? A meta-analysis

Background Context

It is widely accepted that tranexamic acid (TXA) effectively reduces blood losses and transfusions in major surgeries. However, limited studies investigated the role of TXA in conserving blood and saving operative time in spine surgeries.

下调星形细胞上调基因1表达对乳腺癌细胞凋亡的影响

目的:探讨下调星形细胞上调基因1(AEG-1)对乳腺癌细胞凋亡的影响。方法:通过脂质体介导的方法,将乳腺癌MCF-7细胞分别转染AEG-1siRNA(AEG-1siRNA)和阴性对照siRNA(阴性对照组),以无处理的MCF-7细胞为空白对照组。验证转染效果后,分别采用流式细胞术与Westernblot检测各组细胞的凋亡以及凋亡相关蛋白caspase-3和caspase-9的表达。结果:与空白对照组细胞比较,AEG-1siRNA组MCF-7细胞AEG-1蛋白表达明显降低、细胞凋亡率明显升高、caspase-3和caspase-9蛋白表达明显上调(均P0.05);阴性对照组与空白对照组间以上各项指标均无统计学差异(均P0.05)。结论:下调乳腺癌细胞AEG-1的表达能促进caspase-3和caspase-9的表达,从而诱导乳腺癌细胞凋亡,因此,AEG-1在乳腺癌细胞中可能起了抑制细胞凋亡的作用,机制可能与其调节凋亡相关蛋白的表达有关。     

肝癌合并门静脉高压术中脾动脉结扎的临床疗效观察

目的探讨肝癌切除术中行脾动脉结扎治疗肝癌合并门静脉高压的临床疗效。方法回顾性分析2008年1月至2013年1月收治的肝癌合并门静脉高压患者临床资料和手术疗效,对照组患者共33例仅进行肝癌切除术,试验组患者共38例于肝癌切除术中行脾脏动脉结扎。采用SPSS16.0统计软件,对两组患者术前术后1~3个月门静脉压力、血常规检测、脾静脉血流流量等上述指标以x珋±s表示,采用t检验,P<0.05表示差异有统计学意义。结果术后1、2、3个月血象(血细胞三系)和脾静脉血流数值:试验组患者红细胞数、白细胞数、血小板数显著高于对照组(t值分别为:3.457、2.876、2.987;2.975、3.112、2.986;2.964、3.587、3.457。P<0.05),试验组患者脾静脉血流显著低于对照组(t值分别为:2.991、2.989、2.891,P<0.05),两组差异有统计学意义,结果提示脾动脉结扎在短期(4个月)内可明显改善肝硬化所致门静脉高压-脾功能亢进状况。术后4个月,两组患者红细胞数、白细胞数、血小板数及脾静脉血流量比较无明显差异P>0.05。结论肝癌切除术中行脾动脉结扎治疗肝癌合并门静脉高压短期内可有效缓解肝硬化所致门静脉高压-脾功能亢进状况。     

Immunogenicity of branched polyethylene glycol modified interferon alpha

Aim: To assess the immunogenicity of Peginterferon alpha-2?b(Pegberon) and its effect on the efficacy and safety in phase III clinical trial, by comparing it with the control drug Pegasys.

Methods: 770 patients were recruited in total. 509 were treated with Pegberon plus ribavirin and 261 were treated with Pegasys plus ribavirin. After treatment of 12 and 24?weeks, plasma samples were collected from individual patients for detecting the anti-therapeutic antibodies (ATA) and hepatitis C RNA(HCV RNA), to evaluate the production of antibodies and their adverse effect on the efficacy and safety of the treatments. With data obtained from the treatments with Pegberon or Pegasys, gross comparison analysis was performed.

Results: The incidence of treatment-induced neutralizing antibodies (NAb) of Pegberon group (0.7%, 3/454) was significantly lower than Pegasys group (5.0%,12/238)(p?p?=?.010), between baseline NAb positive (36.0%,9/25) and baseline NAb negative patients (76.4%,569/745)(p?p?=?.034). The incidence of potential immunogenicity-related adverse reactions (AR) showed no significant difference between Pegberon (55.6%,283/509) and Pegasys groups (53.6%,140/261)(p?=?.605) and the profiles of these AR were also similar between the two groups.

Conclusion: The incidence of treatment-induced Nab in Pegasys group was significantly higher than the Pegberon group. Baseline ATA, induced ATA and baseline NAb all affected the efficacy. The profiles of potential immunogenicity-related AR were similar between two drug groups, indicating the immunogenicity had no significant adverse effect on safety.